|
| Status |
Public on Apr 19, 2007 |
| Title |
Synergy between PPARgamma ligands and platinum-based drugs in cancer |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
PPARγ is a member of the nuclear receptor family for which agonist ligands have anti-growth effects. However, clinical studies using PPARγ ligands as a monotherapy failed to show a beneficial effect. Here we have studied the effects of PPARγ activation with chemotherapeutic agents in current use for specific cancers. We observed a striking synergy between rosiglitazone and platinum-based drugs in several different cancers both in vitro and using transplantable and chemically induced “spontaneous” tumor models. The effect appears to be due in part to PPARγ-mediated downregulation of metallothioneins, proteins that have been shown to be involved in resistance to platinum-based therapy. These data strongly suggest combining PPARγ agonists and platinum-based drugs for the treatment of certain human cancers
Keywords: Gene expression, change, synergy of interaction
|
| |
|
| Overall design |
Cells were treated with either DMSO/control, rosiglitazone, carboplatin or combination or rosiglitazone and carboplatin in duplicate for 24 hr. RNA was isolated and microarray analysis carried out by the Dana-Farber Cancer Institute Microarray Core.
|
| |
|
| Contributor(s) |
Girnun GD, Naseri E, Vafai SB, Qu L, Szwaya JD, Bronson R, Alberta JA, Spiegelman BM |
| Citation(s) |
17482130 |
| |
| Submission date |
Feb 14, 2007 |
| Last update date |
Aug 10, 2018 |
| Contact name |
Geoffrey Girnun |
| Organization name |
Dana-Farber Cancer Institute
|
| Department |
Cancer Biology
|
| Street address |
One Jimmy Fund Way
|
| City |
Boston |
| State/province |
MA |
| ZIP/Postal code |
02115 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL96 |
[HG-U133A] Affymetrix Human Genome U133A Array |
|
| Samples (8)
|
|
| Relations |
| BioProject |
PRJNA98343 |
Less...
More...